Inactive Trials

1) ESAI E7080- Phase II, multicenter, open-label, single arm trial to evaluate the safety and efficacy of oral E7080 in Medullary and Iodine refractory unresectable differentiated thyroid cancer stratified by histology.
2) A double-blind, randomized phase III study evaluating the efficacy and safety of Sorafenib compared to placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer.
3) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer
4) A Study of RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
5) A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
6) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to assess the efficacy and safety of Vandetanib (Caprelsa) 300 mg in Patients with Differentiated Thyroid Cancer that is either locally advanced or metastatic